
The SCOPE I trial compared the outcomes of transcatheter aortic valve implantation using the ACURATE neo (NEO) and SAPIEN 3 (S3) devices over three years. The trial found that NEO did not meet noninferiority compared to S3 in terms of a composite endpoint at 30 days due to higher rates of valve regurgitation and acute kidney injury. However, after three years, there were no significant differences between NEO and S3 regarding all-cause death, stroke, hospitalization for heart failure, or aortic valve reinterventions. Both devices showed similar functional improvement, and NEO exhibited lower mean gradients.
Like
Save
Share